Keywords
Infliximab
Rheumatoid Arthritis
Psoriatic Arthropathy
Ankylosing Spondylitis
Biosimilar
Pharmacoeconomic
How to Cite
Abstract
Objective: Study the economic impact and persistence of Inflectra® in rheumatoid arthritis (RA), psoriatic arthropathy (PSA), psoriasis, ankylosing spondylitis (AS) naïve, and Remicade® switched patients.
Methods: Retrospective observational cohort study of patients treated with Inflectra® for more than six months in a five years analysis. We collected age, sex, indication, dose, and persistence (in years) for Inflectra® naïve and Remicade® switched patients. Efficacy endpoints included a disease activity score calculator for rheumatoid arthritis (DAS28) and bath ankylosing spondylitis disease activity index (BASDAI). Safety was also assessed. We determined each patient's actual cost of Inflectra® treatment from individualized IV administration and correlated dates during the study period. We simulated the actual cost of these patients if the patients received Remicade®.
Results: During five years, 62 patients (38 women; 31 AS, 18 RA, 13 PSA were treated with Inflectra®. 33 (53%) patients were naïve patients, and 29 (47%) were Remicade® switched patients. In Sept 2019, 33 patients continued on Inflectra® treatment (11 naïve; 22 Remicade® switched) in clinical remission. Twenty-nine patients discontinued therapy, 24 due to relapse, and five due to adverse reactions. All patients with Inflectra® presented a persistence of 24.4±7.4 months. The persistence in naïve patients was 19.1±4.4 months and in Remicade® switched patients was 29.7±5.8 months. The total associated costs of the Inflectra® treatment throughout the observation period were 901.840€. If these patients had been treated with Remicade®, the total cost of therapy would have been 1.099.803€. The use of Inflectra® saved 197,964€ during five years.
Conclusions: Inflectra® produces similar persistence and substantial cost savings when used in Infliximab naïve patients and Remicade® switched patients.
References
Martínez-López de Castro N, Matilla-Fernández MB, Fraga-Fuentes MD, et al. Spanish Society of Hospital Pharmacy position paper on biosimilar medicines. Farm Hosp 2018; 42: 180-183.
Park W, Hrycaj P, Jeka S, et al. A randomized, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013; 72: 1605-12. https://doi.org/10.1136/annrheumdis-2012-203091
Yoo DH, Hrycaj P, Miranda P, et al. A randomised, doublé blind, parallel-group study to demonstrate equivalence in Efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETA study. Ann Rheum Dis 2013; 72: 1613-20. https://doi.org/10.1136/annrheumdis-2012-203090
Park W, Yoo DH, Miranda P, Brzoska M, Wiland P, GutierrezUrena S, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis 2017; 76: 346-54. https://doi.org/10.1136/annrheumdis-2015-208783
Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (Infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther 2015; 15: 1677-83. https://doi.org/10.1517/14712598.2015.1103733
Glintborg B, Sorensen IJ, Loft Ag et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis 2017; 76: 1426-31. https://doi.org/10.1136/annrheumdis-2016-210742
Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24. https://doi.org/10.1002/art.1780310302
Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8. https://doi.org/10.1002/art.1780270401
Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020; 79: 685-99.
Van der Heijde D, Ramiro S, Landewé R et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017; 76: 978-91. https://doi.org/10.1136/annrheumdis-2016-210770
Coates LC, Gossec L, Ramiro S et al. New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. Rheumatology (Oxford) 2017; 56: 1251-53. https://doi.org/10.1093/rheumatology/kew390
García-Lagunar MH, Gutiérrez-Cívicos MR, García-Simón MS et al. Reasons for discontinuation and adverse effects of TNF-α inhibitors in a cohort of patients with rheumatoid arthritis and ankylosing spondylitis. Ann Pharmacother 2017; 51: 388-93. https://doi.org/10.1177/1060028016682330
Nikiphorou E, Hannonen P, Asikainen J, et al. Survival and safety of infliximab biooriginal and Inflectra®(CT-P13) in usual rheumatology care. Clin Exp Rheumatol 2019; 37:
-9.
Kim HA, Lee E, Lee SK, et al. Retention rate and long-term safety of biosimilar CT-P13 in patients with ankylosing spondylitis: data from the Korean College of Rheumatology Biologics registry. Clin Exp Rheumatol 2020; 38: 267-74. https://doi.org/10.55563/clinexprheumatol/z0va6o
Kim TH, Lee SS, Park W, et al. A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Inflectra®CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis. Clin Drug Investig 2020; 40: 541-53. https://doi.org/10.1007/s40261-020-00907-5
Goll GL, Jørgensen KK, Sexton J, et al. Long-term Efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. J Intern Med 2019; 285: 653‐69. https://doi.org/10.1136/annrheumdis-2018-eular.4620
González-Fernández MÁ, Villamañán E, Jiménez-Nácher I, et al. Persistence of biological agents over an eight-year period in rheumatoid arthritis and spondyloarthritis patients. Persistencia de medicamentos biológicos durante ocho años en pacientes con artritis reumatoide y espondiloartritis. Farm Hosp 2019; 43: 24‐30.
Jha A, Upton A, Dunlop Wc, et al. The budget impact of biosimilar infliximab (Remsima) for the treatment of autoimmune diseases in five European countries. Adv Ther 2015; 32: 742-56. https://doi.org/10.1007/s12325-015-0233-1
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.